What Is Otarmeni, and Why Does It Matter?
Otarmeni (lunsotogene parvec-cwha) is a single-use gene therapy for children and adults who have severe or profound hearing loss (a hearing level of more than 90 decibels) caused by confirmed changes in the OTOF gene. But for Otarmeni to work well, it is important that the affected ear has functionally intact outer hair cells and no prior cochlear implant.
Genetic causes account for about half of cases of hearing loss present at birth. One of these causes involves changes in a gene called OTOF, which accounts for about 2%-8% of inherited cases in which only hearing is affected. Normally, the OTOF gene produces a protein called otoferlin that helps conduct sound signals from sensory cells in the inner ear to the brain via the auditory nerve. When a child inherits two nonworking copies of the OTOF gene, their body can't make otoferlin, leading to poor transmission of sounds to the brain, even if the ear itself can detect them. If this type of hearing loss isn't identified early, children may miss the best window for treatment, leading to delays in speech and language development.
Otarmeni uses a modified, non-disease-causing adeno-associated virus (AAV) vector as a carrier to deliver a working copy of the OTOF gene into the inner hair cells in the cochlea (the tiny, spiral-shaped part of the inner ear that helps you hear). The goal is to supply the missing otoferlin protein exclusively to the inner hair cells, so that sound signals can reach the brain via the auditory nerve.
Earlier, OTOF-associated hearing loss was thought to be permanent and managed with lifelong hearing devices. This approval is notable because Otarmeni is the first gene therapy for genetic hearing loss that uses two AAV carriers to deliver the treatment, providing an alternative therapeutic option for people who have the condition.
Why Was It Approved?
The FDA granted accelerated approval to Otarmeni because a clinical study showed that it significantly improved hearing in children with OTOF-associated profound hearing loss. Because this was an accelerated approval, continued approval may depend on results of ongoing studies that would show lasting clinical benefits and confirm the effects on speech and quality of life.
A clinical trial involving 24 pediatric patients, ages 10 months to 16 years, looked at how safe Otarmeni is and well it works. All of the patients had OTOF gene-associated severe to profound sensorineural hearing loss (sounds louder than 90 decibels could be heard). Because there was no separate control group, the results were compared with what usually happens with untreated hearing loss, where improvement is not typically expected. Supporting evidence included laboratory data and confirmation that patients continued to produce the otoferlin protein after treatment.
Among the 20 patients who could be evaluated for effectiveness, 80% showed improved hearing by 24 weeks – something that doesn't normally occur in this condition unless treatment is given. Also, 70% of patients showed improved hearing on the auditory brainstem response test, meaning they could hear sounds at 90 decibels or lower. Among patients who were followed up for 48 weeks, everyone who had improved earlier continued to show benefits, and 42% reached normal hearing levels, including the ability to hear very soft sounds like whispers (25 decibels or lower).
Side effects were common but often manageable. The most frequent side effects included middle ear infection (otitis media), nausea, vomiting, dizziness, rapid involuntary eye movements (nystagmus), balance or walking problems, and pain related to the procedure. Because the therapy is delivered via surgery, serious side effects such as vertigo or ringing in the ear, numbness around the ear, leakage of spinal fluid, facial weakness on the treated side, meningitis or wound infection, infection of the bone behind the ear, a change in taste, and inflammation inside the inner ear can also occur.
What Do I Need to Know?
Otarmeni is supplied with a specialized administration kit and is intended for one-time use. You receive Otarmeni in the operating room as a one-time dose per ear. A surgeon trained in this procedure performs the infusion under general anesthesia. Your health care provider will monitor you after surgery for any complications.
This therapy is not recommended if imaging shows that the inner ear cannot be safely reached. This applies to people with unusual bone development behind the ear or significant structural differences in the middle or inner ear. Your care team will review scans to confirm safe access before scheduling surgery.
Before and after surgery, your health care provider may give you antibiotics to prevent infections and oral steroids to lower inflammation. Let your health care provider know about your or your child's vaccines, so that they can schedule routine vaccines around steroid use (at least a month before the first steroid dose and at least a month after the last dose). Also discuss vaccines that protect against germs causing meningitis because inner ear surgery raises its risk.
For two weeks after treatment, practice careful hygiene because small amounts of the viral vector (AAV) may leave the body through bodily waste. Wash your hands well after contact with diapers or other waste. Seal any items that could be contaminated in a bag before throwing them away.
It is not known whether Otarmeni harms a fetus or passes into breast milk. Before starting Otarmeni, your health care provider will give you a pregnancy test. Talk with your health care provider about your goals and the possible benefits and risks.
Regeneron, the maker of Otarmeni, plans to provide the therapy at no cost to people in the U.S. who meet clinical criteria. You may still be charged for the surgery, anesthesia, and follow-up care. Ask your health care provider and your insurer about coverage and any out-of-pocket costs.